Your browser doesn't support javascript.
loading
TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact.
Braunschmid, Tamara; Kührer, Irene; Mittlböck, Martina; Westerhoff, Maria; Kappel-Latif, Sonja; Brammen, Lindsay; Krishnadath, Kausilia K; Phillips, Wayne A; Gnant, Michael; Kandioler, Daniela.
Afiliación
  • Braunschmid T; Department of Surgery, Medical University of Vienna, Vienna, Austria.
  • Kührer I; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Mittlböck M; Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
  • Westerhoff M; Department of Pathology, University of Michigan, Ann Arbor, Michigan.
  • Kappel-Latif S; Department of Surgery, Research Laboratories, Medical University of Vienna, Vienna, Austria.
  • Brammen L; Department of Surgery, Medical University of Vienna, Vienna, Austria.
  • Krishnadath KK; Department of Translational Gastroenterology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Phillips WA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Gnant M; Department of Surgery, Medical University of Vienna, Vienna, Austria.
  • Kandioler D; Department of Surgery, Medical University of Vienna, Vienna, Austria.
Ann N Y Acad Sci ; 1434(1): 46-53, 2018 12.
Article en En | MEDLINE | ID: mdl-30112858
Technological progress within the last 15-20 years has significantly increased our knowledge about the molecular basis of cancer development, tumor progression, and treatment response. As a consequence, a vast number of biomarkers have been proposed, but only a small fraction of them have found their way into clinical use. The aim of this paper is to describe the specific demands a clinically relevant biomarker should meet and how biomarkers can be tested stepwise. We name this procedure the "triple-R principle": robustness, reproducibility, and relevance. The usefulness of this principle is illustrated with the marker TP53. Since it is mutated in a broad spectrum of cancer entities, TP53 can be considered a very promising marker. Thus, TP53 has been studied in detail but there is still no explicit consensus about its clinical value. By considering our own experience and reviewing the literature, we demonstrate that a major problem of current biomarker research is disregard of whether the biomarker is prognostic or predictive. As an example, it is demonstrated that TP53 is not a prognostic marker, but rather a purely predictive marker, and that disregard of this fact has made this otherwise strong biomarker appear as not being clinically useful so far.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Proteína p53 Supresora de Tumor / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann N Y Acad Sci Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Proteína p53 Supresora de Tumor / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann N Y Acad Sci Año: 2018 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos